Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 41234

New York sues OxyContin maker Purdue Pharma

New York state sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic.

Read More »

FDA declines to approve Pain Therapeutics’ opioid drug

The U.S. FDA declined to approve Pain Therapeutics Inc.’s abuse-deterrent opioid treatment Remoxy for the fourth time.

Read More »

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.

Read More »

U.S. approves first marijuana plant-derived drug

GW Pharmaceuticals Plc’s epilepsy treatment Epidiolex secured FDA marketing clearance, becoming the first cannabis-based drug to be approved in the United States.

Read More »

China says United States domestic opioid market the crux of crisis

China’s drug control agency on Monday said the United States should do more to cut its demand for opioids to tackle the use of the synthetic drug fentanyl, but it vowed to step up cooperation after Chinese production of the substance was blamed for fueling the U.S. opioid crisis.

Read More »

OxyContin Maker Purdue Pharma to Cut 350 More Jobs

Purdue Pharma, which sells the painkiller OxyContin, announced that the company laid off approximately 350 staffers.

Read More »

New research points to universal antibody drug for HIV

AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.

Read More »

Kentucky sues Walgreens Boots Alliance

Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.

Read More »

‘We are still at war’ with Ebola: WHO chief

The head of the World Health Organization cautioned against declaring victory too early in Congo’s Ebola epidemic, despite encouraging signs that it may be brought under control.

Read More »

Nektar Therapeutics’ Big Week: Syndax Cancer Collaboration and New Opioid Submission

Nektar Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the new molecular entity NKTR-181, a mu-opioid agonist for pain relief. The company also inked a non-exclusive clinical collaboration deal with Syndax Pharmaceuticals to develop Nektar’s NKTR-214, a CD122-biased agonist in combination with entinostat, Syndax’s HDAC inhibitor in metastatic melanoma.

Read More »

U.S. biotechs to speed work on Nipah vaccine as virus hits India

A global coalition set up during 2017 to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India.

Read More »

U.S. state lawsuits against Purdue Pharma over opioid epidemic mount

Litigation against OxyContin maker Purdue Pharma LP intensified as six more U.S. states announced lawsuits.

Read More »

Justice Department seeks role in opioid settlement talks

The U.S. Justice Department sought court permission to participate in settlement negotiations aimed at resolving lawsuits by state and local governments against opioid manufacturers and distributors.

Read More »

Opioids no better than NSAIDs for chronic back or arthritis pain

Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests.

Read More »

U.S. seeks time to consider joining opioid litigation

The U.S. Justice Department asked a federal judge overseeing hundreds of lawsuits against opioid manufacturers and distributors to give it 30 days to decide whether to participate in the litigation.

Read More »

Trump urges lawsuit against opioid companies, tougher sentences for dealers

U.S. President Donald Trump called for a federal lawsuit against opioid companies and stiffer penalties for drug dealers, arguing that the government must take a strong approach to combat an opioid addiction epidemic.

Read More »

Indivior bets on $1 billion anti-addiction shot as legal bill weighs

Britain’s Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

Read More »

Opioid makers paid millions to advocacy groups: U.S. Senate report

Five opioid manufacturers including OxyContin maker Purdue Pharma LP paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report.

Read More »

OxyContin maker stops promoting opioids

OxyContin maker Purdue Pharma LP has cut its sales force in half and will stop promoting opioids to physicians, following widespread criticism of the ways that drugmakers market addictive painkillers.

Read More »

Maryland sues Insys to enforce subpoena in opioid probe

Maryland’s attorney general filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc. as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

Read More »

Page 1 of 41234

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation